Teva Pharmaceuticals won U.S. antitrust approval to purchase Allergan’s generics business, after agreeing to sell 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday.
- Teva raises revenue estimates in second quarter
- Teva enjoyed lion’s share of tax breaks in years 2012-13
The $40.5 billion deal, which was announced a year ago, solidifies Teva’s position as the world’s primary maker of generics.
Teva will sell rights and assets related to the 79 pharmaceutical products to 11 rival firms, marking the largest ever drug divestiture order in an FTC pharmaceutical merger case, the commission said in a statement.
Shares of Teva closed up 0.6% at 210.50 shekels ($55.09).
Generics, drugs on which patents have expired and typically a source of healthcare savings, have made headlines over the past year as some drug makers sharply raised prices on medications with few competitors.
“Millions of Americans rely daily on generic drugs to treat a wide range of illnesses,” Debbie Feinstein, director of the FTC’s Bureau of Competition, said in the statement. “The FTC’s settlement safeguards the competitive availability of these medications for patients across the country who depend on them.”
Products being sold include anesthetics, antibiotics, weight-loss drugs, oral contraceptives and treatments for a wide variety of diseases and conditions, the statement said.
The acquirers of the divested drugs include Mayne Pharma Group, Impax Laboratories, Dr. Reddy’s Laboratories, Sagent Pharmaceuticals, Cipla, Zydus Worldwide, Mikah Pharma, and Perrigo Pharma International, according to the FTC.
There has been an unprecedented wave of deals in the healthcare sector since early 2014, from large drug makers buying up smaller rivals, to consolidation among makers of generic medicines and tie-ups between insurers.
Teva, which expects to close the transaction next week, said the combined company would have 338 product registrations pending U.S. regulatory approval and hold the leading position as the initial market entrant for around 115 pending U.S. generic applications.
Teva CEO Erez Vigodman said the deal would generate $1.4 billion in operational and tax savings by the end of 2019 and raise adjusted earnings by 14% next year.